PL1696904T3 - Zastosowanie rotygotyny do leczenia lub do prewencji dopaminergicznej utraty neuronów - Google Patents

Zastosowanie rotygotyny do leczenia lub do prewencji dopaminergicznej utraty neuronów

Info

Publication number: PL1696904T3
Authority: PL; Poland
Prior art keywords: rotigotine; treatment; prevention; neurone loss; dopaminergic neurone
Prior art date: 2003-12-24

Application number

PL04804249T

Other languages

English (en)

Inventor

Dieter Scheller

Frank Dressen

Original Assignee

Ucb Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-24

Filing date

2004-12-23

Publication date

2012-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34706587&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1696904(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-12-23 Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh

2012-04-30 Publication of PL1696904T3 publication Critical patent/PL1696904T3/pl

Links

KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title abstract 3
229960003179 rotigotine Drugs 0.000 title abstract 3
230000002265 prevention Effects 0.000 title abstract 2
230000003291 dopaminomimetic effect Effects 0.000 title 1
230000004770 neurodegeneration Effects 0.000 title 1
230000006378 damage Effects 0.000 abstract 2
210000004002 dopaminergic cell Anatomy 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
208000018737 Parkinson disease Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)

PL04804249T 2003-12-24 2004-12-23 Zastosowanie rotygotyny do leczenia lub do prewencji dopaminergicznej utraty neuronów PL1696904T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10361259A DE10361259A1 (de)	2003-12-24	2003-12-24	Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
PCT/EP2004/014655 WO2005063237A1 (de)	2003-12-24	2004-12-23	Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
EP04804249A EP1696904B1 (de)	2003-12-24	2004-12-23	Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes

Publications (1)

Publication Number	Publication Date
PL1696904T3 true PL1696904T3 (pl)	2012-04-30

Family

ID=34706587

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04804249T PL1696904T3 (pl)	2003-12-24	2004-12-23	Zastosowanie rotygotyny do leczenia lub do prewencji dopaminergicznej utraty neuronów

Country Status (19)

Country	Link
EP (1)	EP1696904B1 (pl)
JP (1)	JP5032125B2 (pl)
KR (1)	KR101296561B1 (pl)
CN (1)	CN1897935B (pl)
AT (1)	ATE533484T1 (pl)
AU (1)	AU2004308648B2 (pl)
BR (1)	BRPI0418195A (pl)
CA (1)	CA2547645C (pl)
DE (1)	DE10361259A1 (pl)
DK (1)	DK1696904T3 (pl)
EA (1)	EA014418B1 (pl)
ES (1)	ES2376881T3 (pl)
IL (1)	IL175891A0 (pl)
IS (1)	IS8493A (pl)
NO (1)	NO20063276L (pl)
NZ (1)	NZ547841A (pl)
PL (1)	PL1696904T3 (pl)
UA (1)	UA85858C2 (pl)
WO (1)	WO2005063237A1 (pl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10361258A1 (de) *	2003-12-24	2005-07-28	Schwarz Pharma Ag	Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) *	2004-03-24	2006-07-06	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CN103175972B (zh) *	2005-10-21	2015-05-20	株式会社芳珂	特应性皮炎标记物及其利用技术
CN101147739B (zh)	2007-07-06	2010-12-08	北京康倍得医药技术开发有限公司	含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
NZ584363A (en)	2007-11-28	2012-11-30	Ucb Pharma Gmbh	Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2
EP2201941A1 (de)	2008-12-29	2010-06-30	UCB Pharma GmbH	Pflaster-Herstellungstechnologie
EP2281559A1 (en)	2009-06-26	2011-02-09	UCB Pharma GmbH	Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
LT3257504T (lt)	2009-12-22	2024-08-26	UCB Biopharma SRL	Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
US8729306B2 (en)	2010-02-05	2014-05-20	Ucb Pharma Gmbh	Process for the preparation of nitrogen substituted aminotetralins derivatives
BR112012029944A2 (pt)	2010-06-25	2019-09-24	Ucb Pharma Gmbh	processo para preparação de derivados de aminotetralinas substituídas com nitrogênio
CN102379873B (zh) *	2010-09-06	2013-10-30	四川大学华西医院	一种急性全身性猴帕金森病模型及其药物筛选方法
EP2559435A1 (en)	2011-08-19	2013-02-20	UCB Pharma GmbH	Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2014037832A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment of epilepsy and neurological diseases
DE102012013439A1 (de)	2012-07-03	2014-01-23	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
WO2013075823A1 (en)	2011-11-22	2013-05-30	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013421A1 (de)	2012-07-03	2014-01-09	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System (TTS) mit Rotigotin
US9399634B2 (en)	2012-05-07	2016-07-26	Cellix Bio Private Limited	Compositions and methods for the treatment of depression
WO2013167985A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of inflammatory disorders
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168016A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of asthma and allergy
WO2013168005A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168012A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
US9499527B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of familial amyloid polyneuropathy
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
WO2013168033A1 (en) *	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neurologic diseases
US9321775B2 (en)	2012-05-10	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of moderate to severe pain
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
US9492409B2 (en)	2012-05-23	2016-11-15	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja)	2012-05-23	2015-07-06	セリックスビオプライヴェートリミテッド	多発性硬化症の治療のための組成物および方法
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264820A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of mucositis
NZ701832A (en)	2012-05-23	2016-08-26	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammatory bowel disease
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en)	2012-09-08	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammation and lipid disorders
TW201431570A (zh)	2012-11-22	2014-08-16	Ucb Pharma Gmbh	用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en)	2013-06-04	2015-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of diabetes and pre-diabetes
JP6726096B2 (ja)	2013-07-03	2020-07-22	エルテーエスローマンテラピー−システメアーゲー	電子部品を有する経皮治療システム
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
CA2948219C (en)	2014-05-20	2023-04-04	Lts Lohmann Therapie-Systeme Ag	Method for adjusting the release of active agent in a transdermal delivery system
US11752110B2 (en)	2014-05-20	2023-09-12	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system including an interface mediator
CN106456566B (zh) *	2014-05-20	2020-06-16	Lts勒曼治疗系统股份公司	含罗替戈汀的经皮递送系统
NZ736131A (en)	2014-09-26	2019-04-26	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es)	2014-09-29	2020-12-16	Cellix Bio Private Ltd	Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja)	2014-10-27	2019-08-21	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
WO2016088132A1 (en)	2014-12-01	2016-06-09	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en)	2015-01-06	2017-08-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of inflammation and pain
RU2717542C9 (ru) *	2016-07-21	2020-08-12	Шаньдун Луе Фармасьютикал Ко., Лтд.	Ротиготина бегенат, его способ получения и применение
ES2966170T3 (es)	2020-01-24	2024-04-18	Luye Pharma Switzerland Ag	Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas
CN112014193B (zh) *	2020-07-24	2021-06-15	武汉大学中南医院	一种新的fj染色方法和装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4564628A (en) *	1983-01-03	1986-01-14	Nelson Research & Development Co.	Substituted 2-aminotetralins
CO5111024A1 (es) *	1998-12-29	2001-12-26	Kimberly Clark Co	Composiciones de recubrimientos de polimero disparado por ion sobre peliculas de polimero sensibles al agua
SE9904723D0 (sv) *	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
JP4228048B2 (ja) *	2000-10-09	2009-02-25	ピーオーダブリューエムアールアイリミテッド	神経変性障害の検出方法
ATE246919T1 (de) *	2001-05-08	2003-08-15	Sanol Arznei Schwarz Gmbh	Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1256339B1 (en) *	2001-05-08	2003-10-15	Schwarz Pharma Ag	Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
FR2828212B1 (fr) *	2001-08-03	2003-10-31	Aventis Pharma Sa	Methodes de diagnostic et de pronostic de la maladie de parkinson
EP1386605A1 (en) *	2002-07-30	2004-02-04	Schwarz Pharma Ag	Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) *	2003-12-24	2005-07-28	Schwarz Pharma Ag	Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) *	2004-03-24	2006-07-06	Schwarz Pharma Ag	Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms

2003
- 2003-12-24 DE DE10361259A patent/DE10361259A1/de not_active Withdrawn
2004
- 2004-12-23 ES ES04804249T patent/ES2376881T3/es not_active Expired - Lifetime
- 2004-12-23 CN CN2004800386660A patent/CN1897935B/zh not_active Expired - Fee Related
- 2004-12-23 JP JP2006546071A patent/JP5032125B2/ja not_active Expired - Fee Related
- 2004-12-23 NZ NZ547841A patent/NZ547841A/en not_active IP Right Cessation
- 2004-12-23 DK DK04804249.3T patent/DK1696904T3/da active
- 2004-12-23 PL PL04804249T patent/PL1696904T3/pl unknown
- 2004-12-23 AU AU2004308648A patent/AU2004308648B2/en not_active Ceased
- 2004-12-23 EP EP04804249A patent/EP1696904B1/de not_active Revoked
- 2004-12-23 EA EA200601227A patent/EA014418B1/ru not_active IP Right Cessation
- 2004-12-23 CA CA2547645A patent/CA2547645C/en not_active Expired - Fee Related
- 2004-12-23 BR BRPI0418195-6A patent/BRPI0418195A/pt not_active IP Right Cessation
- 2004-12-23 KR KR1020067012204A patent/KR101296561B1/ko not_active Expired - Fee Related
- 2004-12-23 AT AT04804249T patent/ATE533484T1/de active
- 2004-12-23 UA UAA200606332A patent/UA85858C2/uk unknown
- 2004-12-23 WO PCT/EP2004/014655 patent/WO2005063237A1/de not_active Ceased
2006
- 2006-05-24 IL IL175891A patent/IL175891A0/en unknown
- 2006-05-31 IS IS8493A patent/IS8493A/is unknown
- 2006-07-14 NO NO20063276A patent/NO20063276L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2004308648B2 (en)	2010-12-16
WO2005063237A1 (de)	2005-07-14
ES2376881T3 (es)	2012-03-20
CA2547645C (en)	2013-07-16
KR101296561B1 (ko)	2013-08-13
EA200601227A1 (ru)	2006-12-29
CN1897935A (zh)	2007-01-17
BRPI0418195A (pt)	2007-06-19
CA2547645A1 (en)	2005-07-14
DK1696904T3 (da)	2012-02-13
IL175891A0 (en)	2006-10-05
HK1094538A1 (en)	2007-04-04
EP1696904A1 (de)	2006-09-06
AU2004308648A1 (en)	2005-07-14
ATE533484T1 (de)	2011-12-15
EP1696904B1 (de)	2011-11-16
CN1897935B (zh)	2010-05-26
NO20063276L (no)	2006-08-30
KR20060109952A (ko)	2006-10-23
UA85858C2 (uk)	2009-03-10
IS8493A (is)	2006-05-31
DE10361259A1 (de)	2005-07-28
EA014418B1 (ru)	2010-12-30
JP5032125B2 (ja)	2012-09-26
JP2007516996A (ja)	2007-06-28
NZ547841A (en)	2011-02-25

Publication	Publication Date	Title
IL175891A0 (en)	2006-10-05	Use of rotigotine for the treatment or prevention of dopaminergic neurone loss
TW200635582A (en)	2006-10-16	Medicaments for the treatment or prevention of fibrotic diseases
IL190150A0 (en)	2008-08-07	New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
MX2007001679A (es)	2007-05-23	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
TW200420550A (en)	2004-10-16	Thiazole compounds for the treatment of neurodegenerative disorders
WO2004041067A3 (en)	2006-12-28	Prevention and treatment of synucleinopathic disease
PT1696905E (pt)	2008-06-09	2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
WO2006020581A3 (en)	2007-03-22	Prevention and treatment of synucleinopathic and amyloidogenic disease
YU37602A (sh)	2005-07-19	Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
TW200505483A (en)	2005-02-16	New medicament compositions based on anticholinergically-effective compounds and β-mimetics
EP2583978A3 (en)	2013-09-11	Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200738242A (en)	2007-10-16	Dihydropteridinones in the treatment of respiratory diseases
PT1594833E (pt)	2008-12-03	Derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
PL370529A1 (pl)	2005-05-30	Zastosowanie pochodnych 2-okso-1-pirolidyny do wytwarzania leku
TW200719882A (en)	2007-06-01	Treatment of connective tissue diseases of the skin
TW200637544A (en)	2006-11-01	Medicaments for the treatment or prevention of fibrotic diseases
WO2005046605A3 (en)	2006-01-26	Compositions and methods of treating neurological diseases
TW200635595A (en)	2006-10-16	Medicaments for the treatment of prevention of fibrotic diseases
ZA200700945B (en)	2008-09-25	Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2007017146A3 (en)	2007-07-26	Use of collismycin and derivatives thereof as oxidative stress inhibitors
IL167848A (en)	2010-11-30	Use of brimonidine in the manufacture of a medicament for treating neurodegenerative conditions
AU2003277298A8 (en)	2004-05-04	Pharmaceutical compositions for treatment of parkinson's disease
TW200519078A (en)	2005-06-16	2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
UY27348A1 (es)	2003-01-31	Imidazotriazinas
SI1817029T1 (sl)	2010-01-29	Derivati izoksazola za lajĺ anje nevropatskih boleäśin